Clinical Trials Logo

Pulmonary Eosinophilia clinical trials

View clinical trials related to Pulmonary Eosinophilia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04049175 Terminated - Clinical trials for Asthma; Eosinophilic

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

PERSEA
Start date: August 28, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.

NCT ID: NCT03052725 Terminated - Eosinophils, Asthma Clinical Trials

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Start date: March 10, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.

NCT ID: NCT02594332 Terminated - Asthma Clinical Trials

Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study

MEMORY
Start date: November 17, 2015
Phase: Phase 3
Study type: Interventional

The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma

NCT ID: NCT01290887 Terminated - Eosinophilic Asthma Clinical Trials

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Start date: June 2011
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.